Results 191 to 200 of about 77,820 (264)

Aseptic meningitis due to intravenous immunoglobulin therapy (IVIG) in therapy‐refractory pyoderma gangraenosum

open access: yes
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Katharina A. Kälber   +3 more
wiley   +1 more source

Efficacy and Safety of Anti‐IL‐4Rα Stapokibart in Elderly Patients With Moderate‐To‐Severe Atopic Dermatitis

open access: yesInternational Journal of Dermatology, EarlyView.
ABSTRACT Background Elderly patients with moderate‐to‐severe atopic dermatitis (AD) often exhibit more heterogeneous inflammatory profiles compared with younger adults. To evaluate the efficacy and safety of stapokibart, an anti‐interleukin‐4 receptor α subunit (IL‐4Rα) monoclonal antibody, in different age subgroups.
Yan Zhao   +26 more
wiley   +1 more source

Casein as rare elicitor of food allergy dependent on augmentation factors ‐ A case report

open access: yes
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Charlotte Jasmin Kiani   +5 more
wiley   +1 more source

Reduced Descending Itch Inhibition in Peripheral Neuropathy Patients With Chronic Pruritus. [PDF]

open access: yesEur J Pain
Eck J   +9 more
europepmc   +1 more source

Minimal Disease Activity as A New Therapeutic Target in Atopic Dermatitis: A 5‐Year Real‐Life Experience With Dupilumab

open access: yesInternational Journal of Dermatology, EarlyView.
ABSTRACT Background Atopic dermatitis (AD) is a chronic inflammatory skin disease with significant physical and psychosocial burden. Dupilumab, a monoclonal antibody targeting IL‐4Rα, has proven to be effective for moderate‐to‐severe AD, but long‐term real‐world data remain limited.
Francesco Leo   +11 more
wiley   +1 more source

Upadacitinib for Immune Checkpoint Inhibitor-Related Dermatitis: A Nonrandomized Clinical Trial.

open access: yesJAMA Oncol
Chen C   +7 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy